Avalyn Pharma
AVLN
93 hedge funds and large institutions have $1.46B invested in Avalyn Pharma in 2026 Q2 according to their latest regulatory filings, with 93 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
99.98% more ownership
Funds ownership: 0% → 99.98% (+100%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$168M |
| 2 |
NHAS
Novo Holdings A/S
Hellerup,
Denmark
|
+$112M |
| 3 |
SOCM
SR One Capital Management
Wayne,
Pennsylvania
|
+$95.5M |
| 4 |
PA
Perceptive Advisors
New York
|
+$77.2M |
| 5 |
SCM
Suvretta Capital Management
New York
|
+$72.2M |
Top Sellers
AVLN Hedge Fund Activity: Q2 2026 in Review
93 of the 8,343 institutional investors tracked by Wall St. Rank reported a position in Avalyn Pharma (AVLN) for Q2 2026, worth a combined $1.46B.
Buyers outnumbered sellers: 93 funds opened new AVLN positions and 0 closed out — a net gain of 93 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Fidelity Investments, opening a new position worth an estimated $168M.
- 93 institutional investors held Avalyn Pharma (AVLN) as of Q2 2026, up from 0 in Q1 2026.
- Funds reported $1.46B of Avalyn Pharma stock for Q2 2026.
- 93 funds opened new Avalyn Pharma positions in Q2 2026 and 0 closed out, a net change of +93 holders.
- The largest Avalyn Pharma buyer in Q2 2026 was Fidelity Investments, an estimated $168M added.
Based on aggregated 13F filings for Q2 2026.